Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials
Titel:
Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials
Auteur:
Trapani, Dario Jin, Qingchun Miller, Kathy D. Rugo, Hope S. Reeder-Hayes, Katherine E. Traina, Tiffany Abdou, Yara Falkson, Carla Abramson, Vandana Ligibel, Jennifer Chen, Wendy Come, Steven Nohria, Anju Ryabin, Nicole Tayob, Nabihah Tolaney, Sara M Burstein, Harold J. Mayer, Erica L.